EFFECT OF STATIN THERAPY ON LIVER FIBROSIS AND ITS ASSESSMENT IN PATIENTS WITH CHRONIC NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT ATHEROSCLEROSIS
Keywords:
statins; non-alcoholic fatty liver disease; NAFLD; non-alcoholic steatohepatitis; NASH; MASLD; MASH; liver fibrosis; atherosclerosis; cardiovascular disease; FIB-4; elastography; magnetic resonance elastography; liver biopsy.Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), now commonly classified within metabolic dysfunction-associated steatotic liver disease (MASLD), frequently coexists with dyslipidemia and atherosclerotic cardiovascular disease. Fibrosis stage is a major determinant of liver-related prognosis, whereas cardiovascular disease remains a major source of morbidity and mortality. Statins are fundamental for prevention of ASCVD events, yet concerns about hepatotoxicity have historically contributed to undertreatment, while experimental and observational data have raised the separate possibility that statins may attenuate hepatic fibrogenesis. [7]
Objective: To evaluate the effects of statin therapy on liver-fibrosis progression and regression in patients with NAFLD/NASH and concomitant atherosclerosis, while synthesizing evidence on mechanisms, cardiovascular outcomes, hepatic safety and the optimal methods for measuring fibrosis change.
Methods: A narrative, non-systematic review was conducted with priority given to literature from approximately September 2016 through September 2026 and to seminal older studies. PubMed/MEDLINE, the Cochrane evidence base, major AASLD, EASL-EASD-EASO and ESC/EAS guidance, and clinical-trial registry information were searched for randomized trials, cohort and case-control studies, systematic reviews/meta-analyses, diagnostic-accuracy studies and mechanistic research. English-language evidence was prioritized, with relevant Russian and Uzbekistan-origin literature considered. No original pooled effect was calculated.
Results: Human observational evidence generally associates statin exposure with less advanced fibrosis or slower progression. In a biopsy-based multicenter cohort, statin use was associated with lower odds of F2–F4 fibrosis (adjusted OR 0.42, 95% CI 0.20–0.80). A nationwide Korean analysis reported an adjusted OR of 0.43 for a BARD-defined significant-fibrosis endpoint. A primary-care cohort found a hazard ratio of 0.60 for progression to FIB-4 ≥2.67. Most importantly for longitudinal imaging, a 16-center cohort of 7,988 patients with steatotic liver disease found statin exposure associated with less liver-stiffness progression both with and without compensated advanced chronic liver disease, but not with significantly more liver-stiffness regression. Meta-analysis has reported lower odds of “significant fibrosis,” but with very high heterogeneity, while the pooled change in fibrosis stage itself was not significant. A short randomized trial containing a rosuvastatin arm showed no significant MRE fibrosis change over 24 weeks. These data support a potential progression-preventing effect more strongly than true regression. [8]
Conclusions: Statins are appropriate and generally safe for ASCVD prevention in patients with NAFLD/MASLD, including compensated advanced liver disease when otherwise clinically indicated. Current evidence does not establish statins as an approved or proven antifibrotic treatment. Evidence is strongest for an association with slower fibrosis/liver-disease progression, whereas convincing demonstration of fibrosis regression remains lacking. Serial assessment should use a multimodal strategy: FIB-4 for triage, VCTE and/or ELF for secondary evaluation, and MRE or biopsy when greater precision is required. Because statins can alter aminotransferases, changes in FIB-4 alone should not be interpreted as proof of collagen regression. [9]
References
1.Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. — 2023. — Vol. 77, no. 5. — P. 1797–1835. — DOI: 10.1097/HEP.0000000000000323. [52]
2.European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. — 2024. — Vol. 81, no. 3. — P. 492–542. — DOI: 10.1016/j.jhep.2024.04.031. [53]
3.Mach F., Koskinas K. C., Roeters van Lennep J. E. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias // European Heart Journal. — 2025. — Vol. 46, no. 42. — P. 4359–4378. — DOI: 10.1093/eurheartj/ehaf190. [32]
4.Dongiovanni P., Petta S., Männistö V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals // Journal of Hepatology. — 2015. — Vol. 63, no. 3. — P. 705–712. — DOI: 10.1016/j.jhep.2015.05.006. [17]
5.Ekstedt M., Franzén L. E., Mathiesen U. L. et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study // Journal of Hepatology. — 2007. — Vol. 47, no. 1. — P. 135–141. — DOI: 10.1016/j.jhep.2007.02.013. [18]
6.Lee J. I., Lee H. W., Lee K. S., Lee H. S., Park J. Y. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study // American Journal of Gastroenterology. — 2021. — Vol. 116, no. 1. — P. 116–124. — DOI: 10.14309/ajg.0000000000000845. [19]
7.Schreiner A. D., Zhang J., Petz C. A. et al. Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD // BMJ Open Gastroenterology. — 2024. — Vol. 11, no. 1. — e001404. — DOI: 10.1136/bmjgast-2024-001404. [20]
8.Zhou X.-D., Kim S. U., Yip T. C.-F. et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease // Gut. — 2024. — Vol. 73, no. 11. — P. 1883–1892. — DOI: 10.1136/gutjnl-2024-333074. [54]
9.Sharma R., Simon T. G., Hagström H. et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease // Clinical Gastroenterology and Hepatology. — 2024. — Vol. 22, no. 4. — P. 749–759.e19. — DOI: 10.1016/j.cgh.2023.04.017. [22]
10.Shah R., Kong A., De Melo S. et al. Association of statins with nonalcoholic fatty liver disease in patients with diabetes // Journal of Investigative Medicine. — 2024. — Vol. 72, no. 6. — P. 497–510. — DOI: 10.1177/10815589241248076. [23]
11.Fatima K., Moeed A., Waqar E. et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis // Clinics and Research in Hepatology and Gastroenterology. — 2022. — Vol. 46, no. 4. — 101816. — DOI: 10.1016/j.clinre.2021.101816. [24]
12.Boutari C. et al. Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis // Clinical Nutrition. — 2022. — Vol. 41, no. 10. — P. 2195–2206. — DOI: 10.1016/j.clnu.2022.08.001. [55]
13.Pastori D., Pani A., Di Rocco A. et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis // British Journal of Clinical Pharmacology. — 2022. — Vol. 88, no. 2. — P. 441–451. — DOI: 10.1111/bcp.14943. [33]
14.Eslami L., Merat S., Malekzadeh R., Nasseri-Moghaddam S., Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis // Cochrane Database of Systematic Reviews. — 2013. — Issue 12. — CD008623. — DOI: 10.1002/14651858.CD008623.pub2.
15.Athyros V. G., Tziomalos K., Gossios T. D. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis // The Lancet. — 2010. — Vol. 376, no. 9756. — P. 1916–1922. — DOI: 10.1016/S0140-6736(10)61272-X. [28]
16.Cho Y., Rhee H., Kim Y.-E. et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study) // BMC Medicine. — 2022. — Vol. 20. — Article 93. — DOI: 10.1186/s12916-022-02288-2. [56]
17.Fang X., Yin Y., Wu Q. et al. Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis // Expert Review of Clinical Pharmacology. — 2025. — Vol. 18, no. 12. — P. 1095–1106. — DOI: 10.1080/17512433.2025.2600410. [57]
18.Cholesterol Treatment Trialists' (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials // The Lancet. — 2026. — Vol. 407, no. 10529. — P. 689–703. — DOI: 10.1016/S0140-6736(25)01578-8. [34]
19.Trebicka J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase // Hepatology. — 2007. — Vol. 46. — P. 242–253. — DOI: 10.1002/hep.21673.
20.Marrone G. et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins // Journal of Hepatology. — 2013. — Vol. 58, no. 1. — P. 98–103. — DOI: 10.1016/j.jhep.2012.08.026. [12]
21.Han S., Choi M., Lee B. et al. Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis // Gut and Liver. — 2022. — Vol. 16, no. 6. — P. 952–963. — DOI: 10.5009/gnl210391. [37]
22.Selvaraj E. A., Mózes F. E., Jayaswal A. N. A. et al.; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis // Journal of Hepatology. — 2021. — Vol. 75, no. 4. — P. 770–785. — DOI: 10.1016/j.jhep.2021.04.044. [39]
23.Loomba R. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study // Hepatology. — 2014. — Vol. 60. — P. 1919–1927. — DOI: 10.1002/hep.27362.
24.Ratziu V., Charlotte F., Heurtier A. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease // Gastroenterology. — 2005. — Vol. 128, no. 7. — P. 1898–1906. — DOI: 10.1053/j.gastro.2005.03.084.
25.Kronborg T. M., Schierwagen R., Trošt K. et al. Atorvastatin for patients with cirrhosis: a randomized, placebo-controlled trial // Hepatology Communications. — 2023. — Vol. 7, no. 12. — e0332. — DOI: 10.1097/HC9.0000000000000332. [35]
26.Lazebnik L. B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version [in Russian] // Experimental and Clinical Gastroenterology. — 2021. — Vol. 185, no. 1. — P. 4–52. — DOI: 10.31146/1682-8658-ecg-185-1-4-52. [58]
27.Sadikova D. Sh., Khaydarova F., Esimova D. M. Construction of computer model for diagnostics and monitoring of non-alcoholic fatty liver disease // Uzbek Medical Journal. — 2021. — Vol. 2, no. 2. — P. 9–14. — DOI: 10.26739/2181-0664-2021-2-2. [59]
28.ClinicalTrials.gov. Study of atorvastatin therapy in patients with nonalcoholic steatohepatitis and significant fibrosis. — Clinical trial registry record NCT04679376. — DOI: not applicable to the registry record. Status and completion information should be rechecked before publication of the final manuscript because the study remained within its reported trial timeline at the September 13, 2026 literature cutoff. [27]
